title: Brain and plasma levels of opioid peptides are altered in rats with thioacetamide-induced fulminant hepatic failure: implications for the treatment of hepatic encephalopathy with opioid antagonists.
abstract: Although plasma levels of Met-enkephalin and beta-endorphin are elevated in patients suffering from liver failure, it is not known whether central nervous system (CNS) opioidergic neurotransmission is altered in these patients. Such changes may contribute to the motor dysfunction, psychiatric abnormalities and CNS depression observed in hepatic encephalopathy (HE). Therefore, Met- and Leu-enkephalin, dynorphin A and beta-endorphin levels were measured in discrete brain regions and plasma from thioacetamide-treated rats in Stages II to IV of HE. Pituitary and plasma beta-endorphin, Met- and Leu-enkephalin concentrations increased with the severity of HE by 50 to 290%. Pituitary and brainstem dynorphin A levels increased whereas plasma levels decreased in rats with thioacetamide-induced fulminant hepatic failure. Both striatal Met- and Leu-enkephalin levels increased and hypothalamic concentrations decreased in HE. Concurrent with the increase in striatal Met-enkephalin levels was a 26 to 48% decrease in the density of striatal and hypothalamic delta receptors. No change in either the density or affinity of radioligand binding to mu or delta receptors was observed in the CNS. Finally, administering (+/-)-naloxone (5 and 10 mg/kg) or (+/-)-naltrexone (5-15 mg/kg), but not (+)-naloxone (10 mg/kg), significantly increased the motor activity of rats with Stage III HE. Whereas elevated plasma levels of opioid peptides may play a role in the peripheral manifestations of hepatic failure (ascites and hypotension), increased CNS levels of these peptides may be involved in the neuropsychiatric abnormalities characteristic of HE. Thus, opioid antagonists may be effective in ameliorating some of the neurological manifestations of HE.
authors.affiliation: Laboratory of Neuroscience, National Institute of Arthritis, Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA.
authors.forename: C
authors.initials: C
authors.lastname: Yurdaydin
authors.forename: Y
authors.initials: Y
authors.lastname: Li
authors.forename: J H
authors.initials: JH
authors.lastname: Ha
authors.forename: E A
authors.initials: EA
authors.lastname: Jones
authors.forename: R
authors.initials: R
authors.lastname: Rothman
authors.forename: A S
authors.initials: AS
authors.lastname: Basile
mesh_terms: D000818:Animals; D001923:Brain Chemistry; D004399:Dynorphins / Q000032:analysis; D004743:Enkephalin, Leucine / Q000032:analysis; D004744:Enkephalin, Methionine / Q000032:analysis; D006501:Hepatic Encephalopathy / Q000139:chemically induced / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D009292:Narcotic Antagonists / Q000627:therapeutic use*; D018847:Opioid Peptides / Q000032:analysis* / Q000097:blood; D051381:Rats; D017207:Rats, Sprague-Dawley; D013853:Thioacetamide; D001615:beta-Endorphin / Q000032:analysis
chemical_list: D009292:Narcotic Antagonists; D018847:Opioid Peptides; D013853:Thioacetamide; D004744:Enkephalin, Methionine; D004743:Enkephalin, Leucine; D001615:beta-Endorphin; D004399:Dynorphins